Hot Topic! Managing the demands of safety reporting for the COVID-19 response


COVID-19 brings new challenges to pharmacovigilance teams as outdated and often disjointed processes are stressed by the incoming wave safety reports resulting from the accelerated approval of new treatments and the implementation of mass vaccination campaigns.

In this presentation, originally given at the World Drug Safety Conference Americas 2020, Dr Andrew Rut discusses the challenges of managing adverse event intake and processing in a fast-paced and high impact development cycle and outline how digital transformation of pharmacovigilance means we are better placed to manage post approval safety monitoring during the COVID-19 response.

Request More Information

To find out more or request a demo fill in the details below:

By submitting your information, you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing


We use analytical cookies that need your permission. For more details and advanced options view our Cookies Policy.